Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
The Japanese drugmaker is trying to shore up its product pipeline ahead of April 2015 when patents on its best-selling schizophrenia drug Abilify expire.
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
Martin Shkreli, the ousted CEO of Retrophin, received $3 million from selling company stock but delayed disclosure for two months, a new SEC filing shows.
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.
BioMarin is betting that its experience in securing approvals for "orphan-disease" drugs can help Prosensa win approval for drisapersen, an experimental treatment for Duchenne muscular dystrophy.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.